# Trial Design and Baseline Characteristics from REMODEL: A Mechanistic Study of Semaglutide vs. Placebo in People with Type 2 Diabetes and CKD

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/trial-design-and-baseline-characteristics-from-remodel-a-mechanistic-study-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | David Z.I. Cherney,Petter Bjornstad,Milenta Mariam Chacko,Thomas P. Gunnarsson,Jeffrey B. Hodgin,Matthias Kretzler,Nicolas Belmar,Menno Pruijm,Philip Andreas Schytz,Katherine R. Tuttle |
| Citations | 2 |
| DOI | 10.1681/asn.2024wcjmwep0 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4403833629 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Nicolas Belmar](https://scholariq.org/researchers/nicolas-belmar/)

## Paper journal

- [Journal of the American Society of Nephrology](https://scholariq.org/journals/journal-of-the-american-society-of-nephrology/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.